Title: An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study.
April 2023 Journal of Thrombosis and Haemostasis. Volume 1 Issue 4
DOI: https://doi.org/10.1016/j.jtha.2022.11.041
6 March 2023 Latest news on the development of a prophylactic treatment for FNAIT.
NEW HAVEN, Conn.–(BUSINESS WIRE)–Mar. 6, 2023– Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects.